Active Ingredient: Cis-Diaminedichloroplatinum
To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours of ovary carcinoma (stages III and IV).
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
50 - 120 mg per m² of body surface area (BSA)
From 50 To 120 mg per m² of body surface area (BSA) once every 21 day(s)
The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of a combination chemotherapy. The dosage directions are applicable for both adults and children. For recommendations on the dosage applicable, based on the diagnosis and the clinical condition, the current medical literature should be consulted.
For monotherapy, the following two dosage regimens are recommended:
Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; 15 to 20 mg/m²/day for five days, every 3 to 4 weeks.
If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks unless in the combination therapy of small-cell and non-small-cell lung carcinoma, in which a typical dose of 80 mg/m² is administered.
Further dosage recommendations are to be based upon current medical insights, to be obtained from the literature or/and the appropriate working parties.
In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately.
The cisplatin solution for infusion prepared according to instructions should be administered by intravenous infusion over a period of 6 to 8 hours.
Intravenous
15 - 20 mg per m² of body surface area (BSA)
From 15 To 20 mg per m² of body surface area (BSA) once every day for 5 day(s)
The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of a combination chemotherapy. The dosage directions are applicable for both adults and children. For recommendations on the dosage applicable, based on the diagnosis and the clinical condition, the current medical literature should be consulted.
For monotherapy, the following two dosage regimens are recommended:
Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; 15 to 20 mg/m²/day for five days, every 3 to 4 weeks.
If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks unless in the combination therapy of small-cell and non-small-cell lung carcinoma, in which a typical dose of 80 mg/m² is administered.
Further dosage recommendations are to be based upon current medical insights, to be obtained from the literature or/and the appropriate working parties.
In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately.
The cisplatin solution for infusion prepared according to instructions should be administered by intravenous infusion over a period of 6 to 8 hours.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
